Corient Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Corient Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$309K	Hold	2,121	–	–	0.02%	450
2022 Q2	$309K	Sell	2,121 -155	-7%	-$22K	0.02%	464
2022 Q1	$372K	Sell	2,276 -36	-2%	-$5.49K	0.02%	461
2021 Q4	$392K	Buy	2,312 +38	+2%	+$7.06K	0.03%	432
2021 Q3	$429K	Buy	2,274 +246	+12%	+$46.1K	0.03%	400
2021 Q2	$344K	Buy	2,028 +198	+11%	+$29K	0.03%	455
2021 Q1	$258K	Buy	1,830 +219	+14%	+$33K	0.02%	491
2020 Q4	$209K	Buy	+1,611	New	+$215K	0.02%	468
2020 Q3	–	Sell	-1,460	Closed	-$216K	–	509
2020 Q2	$216K	Buy	+1,460	New	+$197K	0.03%	416

Other funds holding ALNY

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Corient Capital Partners's ALNY Position: Q3 2022 in Review

Corient Capital Partners held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2022 at 2,121 shares worth $309K. The position accounts for 0.02% of the portfolio, ranked #450.

Corient Capital Partners first reported a position in ALNY in Q2 2020 and has held it in 9 quarters since. The position peaked at $429K in Q3 2021. 496 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

Corient Capital Partners held 2,121 shares of Alnylam Pharmaceuticals worth $309K as of Q3 2022.
Corient Capital Partners left its Alnylam Pharmaceuticals share count unchanged in Q3 2022.
Alnylam Pharmaceuticals made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #450 holding.
Corient Capital Partners first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
Corient Capital Partners's Alnylam Pharmaceuticals position peaked at $429K in Q3 2021.
496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.